Pulmonary drug delivery devices market seen reaching $71.9 billion by 2030

The pulmonary drug delivery devices market is projected to grow from $52.8 billion in 2025 to $71.9 billion by 2030, driven by rising respiratory disease rates, digital inhaler adoption and home-based care. North America led the market in 2025 as demand builds for more targeted, non-invasive treatment options.

Why it matters: - Pulmonary drug delivery devices are becoming more important as respiratory disease burden rises worldwide. - The market outlook points to steady growth in tools that deliver medicine directly to the lungs, where they can act faster and support both respiratory and some systemic treatments. - The shift also reflects broader demand for non-invasive care, home treatment and digital monitoring in chronic disease management.

What happened: - The Business Research Company said the pulmonary drug delivery devices market will rise from $52.8 billion in 2025 to $56.49 billion in 2026. - The market is forecast to reach $71.9 billion by 2030. - The company put 2025-2026 growth at a 7.0% CAGR and 2026-2030 growth at a 6.2% CAGR. - The report covers market size, trends and global forecasts for 2026-2035. - A free sample report is available here. - The full report is available here.

The details: - Growth has been linked to higher respiratory disease rates, greater use of inhalation therapies, broader asthma and COPD treatment programs, better inhaler design and growing awareness of pulmonary drug delivery. - Future demand is expected to come from personalized respiratory care, digital health-integrated inhalers, home-based respiratory treatment, non-invasive delivery and new inhalation technologies. - Rising respiratory disorders are being driven by air pollution, smoking, urbanization, climate change and an aging population. - A December 2023 JAMA Network Open study projected global COPD cases could approach 600 million by 2050, a 23% increase in prevalence. - North America held the largest share of the global market in 2025. - The report also tracks Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The devices are used mainly for asthma and COPD, and they also support systemic absorption of drugs such as insulin and pain relief medications. - The 2026 report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.

Between the lines: - Smart and connected inhalers are moving from niche products toward a more central role because they can track use and support adherence. - Mesh and ultrasonic nebulizers, along with combination drug-device products, signal a market moving toward more targeted and patient-friendly delivery systems. - North America's lead suggests advanced respiratory care infrastructure still shapes adoption, while other regions may grow faster as access improves.

What's next: - The market is expected to keep expanding through 2030 as respiratory care shifts further toward connected, home-based and personalized delivery. - Companies and health systems will likely keep investing in inhalation technologies that improve adherence, monitoring and treatment efficiency. - Regional growth outside North America may accelerate if healthcare infrastructure and chronic disease management continue to improve.

The bottom line: - Pulmonary drug delivery devices are moving from a specialized treatment category to a bigger part of chronic respiratory care, with digital features and non-invasive delivery emerging as key growth drivers.